Forbidden to Drive – a New Chemotherapy Side Effect

Rk, Rovere; As, De Lima

doi:10.14735/amko2015370

Cited by 8 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hand and foot syndrome has been proposed as one of the reasons for unrecognizable fingerprints in patients on chemotherapeutic agents, although there is no consensus on this …”

Section: Discussionmentioning

confidence: 99%

“…However, post‐treatment fingerprints were not assessed in most patients . Also, when other individuals were surveyed after stopping capecitabine, the loss of fingerprints persisted in some patients . We have not followed our patients to assess the reversibility of their fingerprint changes.…”

Section: Discussionmentioning

confidence: 99%

“…Fingerprints can fade or become damaged in some situations, such as dermatitis, leprosy, electric and radiation injuries, and use of topical corticosteroids for treatment of eczema . In recent years, there have been studies indicating that fingerprints could be altered or lost with the use of some chemotherapeutic agents, including capecitabine and paclitaxel …”

Section: What Is Known and Objectivementioning

confidence: 99%

“…In recent years, some studies have indicated that HFS could lead to fingerprint changes or loss. However, this association is controversial . Our study aimed to evaluate the incidence of fingerprint changes in patients treated with capecitabine‐containing chemotherapy regimens and its relations to the various grades of HFS.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…However, this association is controversial. [3][4][5][6][7][8][9][10][11][12][13] Our study aimed to evaluate the incidence of fingerprint changes in patients treated with capecitabine-containing chemotherapy regimens and its relations to the various grades of HFS.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Capecitabine induced fingerprint changes

et al. 2019

View full text Add to dashboard Cite

What is known and objective Fingerprinting is recognized as an easily accessible means of personal identification; however, fingerprints can be damaged after administration of some chemotherapy agents that result in hand and foot syndrome (HFS). Fingerprint loss may also be due to reasons unrelated to HFS. This study evaluated the incidence of fingerprint changes in patients treated with capecitabine‐containing chemotherapy regimens and its relations to various grades of HFS. Methods Seventy‐one patients who received chemotherapy with or without capecitabine as part of their regimen were enrolled in the study. Fingerprints were collected once before the initiation of chemotherapy and once after the third course of chemotherapy. The fingerprints were examined by the Iranian Society of Forensic Physicians, for probable changes in the post‐chemotherapy states. Results and discussion Thirty‐seven patients were enrolled in the capecitabine group and 34 in a comparison group. Fingerprint changes were observed in 25 (67.6%) of the 37 patients in the capecitabine group and none in the comparison group. There was no correlation between the occurrence or severity of HFS and fingerprint changes (P = 0.880). In capecitabine group, the total dose and course numbers of capecitabine were not significant in patients with and without fingerprint changes. What is new and conclusion Based on our findings, we recommend notifying patients who are considered for capecitabine therapy about the risk of fingerprint changes before the initiation of treatment, as this may have legal implications.

show abstract

“…Hand and foot syndrome has been proposed as one of the reasons for unrecognizable fingerprints in patients on chemotherapeutic agents, although there is no consensus on this …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Capecitabine induced fingerprint changes

et al. 2019

View full text Add to dashboard Cite

show abstract

Capecitabine and the Risk of Fingerprint Loss

Doorn

Veelenturf²,

Binkhorst

et al. 2017

JAMA Oncol

View full text Add to dashboard Cite

Anticancer treatments are frequently accompanied by cutaneous adverse effects: capecitabine treatment induces handfoot syndrome (HFS) in approximately 50% to 60% of patients, whereas hand-foot skin reaction (HFSR) has been reported in 19% to 34% of patients treated with the tyrosine kinase inhibitors (TKIs) sunitinib malate or sorafenib tosylate. 1 Ultimately, these cutaneous adverse events are believed to result in the loss of fingerprints, which, to our knowledge, has been described anecdotally for patients treated with capecitabine 2-6 and can cause serious identification problems. We assessed the association of HFS and HFSR with fingerprint quality.Methods | This prospective cohort study was performed at the Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and included 337 ten-fingerprint sets from 150 patients. The principal inclusion criterion was a planned daily treatment with capecitabine (as monotherapy or combination therapy) or a TKI. Previous treatment with these drugs was not allowed. Fingerprints were taken from all patients' fingers using a digital fingerprint scanner (MorphoLivescan; Morpho) before treatment, within 6 to 10 weeks after the start of treatment, and after treatment discontinuation. At the same time, digital photographic images (Nikon Corporation) were made of the palms and fingers of patients to detect abnormalities that could affect the fingerprints. Three dactyloscopists and a detective from the Netherlands National Police Agency visually assessed fingerprints and images, respectively. The baseline fingerprints were compared with the fingerprints during treatment and were scored on the overall quality of friction ridge details and the suitability for individualization purposes. A 5-point scale was used on which slight improvement was scored as 1, no changes as 2, slightly decreased quality as 3, major loss of quality as 4, and total loss of fingerprint quality as 5. The scores were averaged, and, subsequently, these results were dichotomized to severe quality loss (score 4-5) or no severe changes in fingerprints (score 1-3). The severity levels of HFS and HFSR were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03. Groups were compared using a χ 2 test. The institutional review board of the Erasmus MC Cancer Institute approved the study protocol, and written informed consent was obtained from all patients.

show abstract

Capecitabine

2016

Reactions Weekly

View full text Add to dashboard Cite

Forbidden to Drive – a New Chemotherapy Side Effect

Cited by 8 publications

References 4 publications

Capecitabine induced fingerprint changes

Capecitabine induced fingerprint changes

Capecitabine and the Risk of Fingerprint Loss

Capecitabine

Contact Info

Product

Resources

About